Atlas Trials

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Clinical trial NCT01160445 · TERMINATED

Trial details

NCT number
NCT01160445
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic MelanomaMetastatic Renal Cancer
Start date
2010-06-01
Primary completion
2012-01-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.